Fowler D.R.,American Medical Systems Inc.
AMA journal of ethics | Year: 2016
Death certificates and autopsy reports contain personal identifying information and clinical information protected under the Health Insurance Portability and Accountability Act (HIPAA) of 1996. These documents are used, for example, by the families of the deceased for settling estates, bereavement and closure, and genetic counseling of relatives. Insurance companies, public health and law enforcement officials, and the legal community also have legitimate claims to this information. Critical ethical questions have not yet been settled about whether and when this information should be public and under which circumstances making this kind of information public incurs benefits, harms, or both. Additional considerations include which organizations-the media, academic institutions, or government agencies, for example-are best suited to interpret these questions and respond to them. © 2016 American Medical Association. All Rights Reserved.
Kang H.W.,American Medical Systems Inc. |
Peng Y.S.,American Medical Systems Inc. |
Stinson D.,American Medical Systems Inc.
Journal of Urology | Year: 2010
Purpose: We investigated the effect of 120 to 200 W high power levels on in vitro vaporization of bovine prostate using a custom-made 532 nm lithium triborate laser system. Materials and Methods: Light (532 nm) delivered through a newly designed 750 μm core diameter side firing prototype fiber vaporized 114 bovine prostate tissue specimens in saline at 20C using a 2-dimensional scanning system. Various conditions were tested, including 120 to 200 W power, 1 to 5 mm working distance and 2 to 8 mm per second treatment speed. Results: Regardless of treatment speed 180 W was the optimal power to maximize tissue vaporization efficiency by removing 80% more tissue than at 120 W. At 120 and 180 W laser light vaporized tissue more efficiently at a 4 mm per second treatment speed and vaporized equally efficiently at up to 3 mm working distance. At the slowest treatment speed the mean thickness of the coagulation zone at 180 W was 20% thicker than at 120 W (1.31 vs 1.09 mm) but still thin, comparable to previous findings of 1 to 2 mm. Conclusions: In vitro the 532 nm lithium triborate laser showed that 180 W is the optimal power to maximize tissue vaporization efficiency with enhanced coagulation characteristics. These desirable outcomes must be validated in vivo. © 2010 American Urological Association Education and Research, Inc.
News Article | August 15, 2013
NxThera said it closed on a Series C round worth $18.2 million and won CE Mark approval for its Rezum treatment for benign prostatic hyperplasia. Maple Grove, Minn.-based NxThera’s device uses steam to reduce the size of the prostate to relieve urinary symptoms from BPH, according to NxThera’s website. NxThera did not name any of the investors in its C round, but Arboretum Ventures, American Medical Systems, Aberdare Ventures and GDN Holdings (the investment firm of former Medtronic vice chairman Dr. Glen Nelson) all participated in a $12.6 million Series B round back in 2011. The company said it plans to use the Series C round to back a clinical trial ahead of a bid for U.S. clearance for the Rezum device, to commercialize the treatment in Europe and to look into using its sterile water vapor technology in treating prostate cancer and kidney cancer. "We sincerely appreciate the continued engagement and support of our investors as we move closer to realizing NxThera’s vision of a fundamentally new treatment approach that will transform the experience of urologists and the millions of men they treat who suffer from prostate conditions," president & CEO Bob Paulson said in prepared remarks. "With this round of financing, we are well-positioned to undertake and complete our U.S. BPH pivotal trial, obtain early commercial BPH experience in Europe, and accelerate our prostate and kidney cancer clinical development programs."
News Article | March 24, 2015
(http://www.researchandmarkets.com/research/8st7zk/medical_fiber) has announced the addition of the "Medical Fiber Optics - Global Strategic Business Report" report to their offering. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Medical Fiber Optics in US$ Thousands by the following Applications: Fiberoptic Surgical Lights, Fiberoptic Dental Lights, Optic Fiber Endoscopes, Laser Fiberoptics, Fiberoptic Sensors, and Others. The report profiles 61 companies including many key and niche players such as:
News Article | April 30, 2015
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/gfgvcx/global_urinary) has announced the addition of the "Global Urinary Incontinence Products Market 2015-2019" report to their offering. The Global Urinary Incontinence Products market to grow at a CAGR of 8.12% over the period 2014-2019. This report covers the present scenario and the growth prospects of the Global Urinary Incontinence Products market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of different types of urinary incontinence treatment products. Emerging countries such as China, India, South Korea, and Thailand have a growing elderly population who are mostly price sensitive and have limited awareness about urinary incontinence. Growing awareness programs about the disease and personal hygiene, commercial advertisements, and increased disposable income of middle and upper-class consumers have propelled the growth of the market. According to the report, improved living conditions and quality of healthcare are increasing the demand for devices such as urinary catheters for the treatment of urologic disorders. Further, the report states that the economic burden of UUI, which includes direct, indirect, and intangible costs, inhibits the growth of the market.
News Article | April 21, 2015
ATLANTA--(BUSINESS WIRE)--In support of its mission to educate, support and encourage men to make healthier lifestyle choices to prevent disease, the Men’s Health & Wellness Center is pleased to join ZERO - The Project to End Prostate Cancer to present the Dash4Dad 5k Race / 1 Mile Fun Walk / Kids Superhero Dash For Dad on Saturday, June 20, 2015. The race is part of the Great Prostate Cancer Challenge, America’s Premier Men’s Health Event Series, taking place in 40 cities in 2015. The Dash4Dad event will begin at 8:00 A.M., rain or shine, on Saturday, June 20, 2015 in the Home Depot/Costco Parking Lot located at 6400 Peachtree Dunwoody Road in Sandy Springs, GA. Individual runner/walker pre-registration fee is $25 until May 26th, $30 from May 27th through June 20th and $35 the day of the race. Children under 12 pre-registration fee is $15. Snooze for Dudes is $35. Registration forms may be found online at www.zeroprostatecancerrun.org/atlanta. Cancer survivors please contact Joe Blumberg at the information provided below for FREE registration. Survivors receive special recognition at the event. It is anticipated that more than 1,000 participants will join in this event to defeat prostate cancer and maintain screening and patient support programs here in Georgia. Prizes will be awarded to winners in multiple age brackets. Technical T-shirts and refreshments will also be provided for all registered competitors by Dash4Dad sponsors. The event’s local sponsors include: Presenting sponsor Northside Hospital, Georgia Urology, Dewberry Foundation, American Medical Systems, Dendreon, UPS and Radiotherapy Clinics of Georgia. Media sponsors include WXIA 11 Alive, WSB AM750 and AM680 The Fan. The Men’s Health & Wellness Center, a nonprofit center opened in 2007, provides free prostate cancer screening and support groups in the Atlanta area. We provide education and support for men and their loved ones before, during and after a health crisis. For more information, visit www.4dad.org. About ZERO – The Project to End Prostate Cancer We commit ourselves not only to reduce prostate cancer and alleviate the pain from the disease, but to end it. We see a future where all men who have been diagnosed with prostate cancer will be cured or can manage their illness with high quality of life, with the support they need to minimize physical and emotional suffering, and to cope effectively throughout their cancer journey, visit www.zeroprostatecancer.org.
News Article | March 14, 2011
Fear and Coding on the StartupBus: Wired.com reporter Keith Axline was embedded on a StartupBus bound for the South by Southwest conference in Austin, Texas. It was one of six such buses filled with coders competing to turn bright ideas into startup prototypes during the 48-hour road trip. The buses have arrived at SXSW, but the journey continues. AUSTIN, Texas — Though the StartupBus finalists for Monday’s judges' panel have already been decided, many of the companies that didn’t make the cut churned out interesting products. Four teams from the Silicon Valley bus carrying "buspreneurs" from San Francisco made it to the semifinals at the South by Southwest Interactive conference, more than any other StartupBus. Our high-speed business incubator had its fair share of technical problems, which brought us all closer together as a community. "Essential Wi-Fi only — if you're watching YouTube videos I'll shoot you in the face," said SpeakerMeter team member Pamela Fox wryly at a particularly spotty leg of the trip. Oddly, it's moments like these that make the whirlwind coding marathon memorable. The teams that appear in the photo gallery above no longer have a chance to win the 2011 StartupBus competition. (My team, WalkIN, will be representing our bus at the finals.) But in many cases, this year's crop of buspreneurs created functioning products that don't need the judges' anointment to be viable. They're free to pursue investment on their own with the not-insignificant credibility of having survived the StartupBus. Which teams would get your vote? Meet the rest of the Silicon Valley StartupBus' occupants and decide for yourself. This service aggregates information about pregnancy, from conception to birth, and sends users timely text-message updates about what they should be doing and planning for at each stage. "It's texting from the womb," says the service's slogan. The open source information is vetted by a small team of doctors. Push Baby Push also has an OB/GYN and pediatrician lined up as advisers. Just text your due date to the service's number and begin receiving tips. • Joseph Skerbec, system analyst at American Medical Systems • Dave Cascino, software developer at Knewton.com in New York City • Mat Wiemann, entrepreneur from Germany On the web: Push Baby Push website, Tumblr blog and Twitter: @pbabyp
News Article | July 17, 2015
Until the early 1970s, if problems with penile blood flow or nerve function meant a guy couldn’t get it up, his choices for treatment were pretty limited, and certainly did not mimic nature. There were external props that could be strapped to a flaccid penis. There were a few implantable props that made the penis permanently stiff, but men using these devices not only had to worry about all the issues of having a permanent boner, sometimes the devices would rub a hole through the skin and fall out. Eew. Berish Strauch thought an inflatable option might work better, and the development of flexible plastics made it possible. In 1973, he proposed an implantable device that would embed a fluid reservoir (22 in the diagram above) inside the scrotum (12) or the abdomen (14), connected to a flexible tube (18) running along the top of the penile shaft (16). The impotent patient could pump the tube full whenever he felt like some sexytime. In this way it is possible to stretch and elongate the tube and render it relatively rigid so as that a penile erection will result. The return of the fluid under pressure from the time to the container is delayed so that an erection will be maintained for a satisfactory period of time. Fluid would be locked inside the tube by a series of tiny metal pressure plates. Getting the fluid out of the penis was decidedly manual. It’s like masturbating in the mirror universe. Strauch never developed his design. Instead, he sold the idea to American Medical Systems, where Brantley Scott and his colleagues refined it: turning the elastic tube into a pair of balloon like reservoirs, and implanting them inside the penile erectile bodies. Improved versions of that design are still in use today.
News Article | May 11, 2015
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/v42kn4/urinary) has announced the addition of the "Urinary Incontinence Products Market in the US 2015-2019" report to their offering. Urinary incontinence is any type of involuntary urine leakage. It may occur as a result of an abnormal function of the lower urinary tract, overactive bladder, or other illnesses. It is estimated that about 50 percent of women suffer from urinary incontinence at some point in their lives. In men, the prevalence is 5 percent, and most cases are related to prostate diseases. The severity depends on the psychological, physical, and social well-being of the affected individuals. The author recognizes the following companies as the key players in Urinary Incontinence Products Market in the US 2015-2019: American Medical Systems, C.R. Bard, Coloplast, Covidien, Kimberly-Clark and Svenska Cellulosa Aktiebolaget. Commenting on the report, an analyst from the team said: The market is witnessing changes in the design of core products and the usage of complex engineered fabrics. Advances in technology have led to the development of comfortable thin adult diapers with increased fluid absorption and retention capacity. In addition, advances in sling procedures have led to MI surgery that doesn't compromise patient safety. Traditional treatment options involved many risks and complications, which included pain and long recovery periods and hospital stays. Innovation, cost optimization, and high manufacturing efficiency have changed the dynamics of the market. Urinary incontinence is the third most common type of disorder in patients aged 65 or above, and nearly 13 million people in the US are affected by it. Further, the report states that social and economic constraints are a major challenge in the market. Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.